

DAFTAR PUSTAKA

1. Purnomo BB. Dasar-dasar Urologi. Edisi ke-3. Malang: Sagung Seto; 2016. hal. 125-44.
2. Ikatan Ahli Urologi Indonesia. Pedoman Penatalaksanaan Klinis Benign Prostat Hyperplasia. Jakarta: IAU; 2017.
3. Samsuhidajat R. Buku Ajar Ilmu Bedah Samsuhidajat-de Jong. Edisi ke-3. Jakarta: EGC;2011. hal. 706-22.
4. BPS (2019). Angka Harapan Hidup Indonesia. Badan Pusat Statistik. Tersedia di <https://www.bps.go.id/linkTableDinamis/view/id/1114>.- Diakses pada April 2020.
5. BPS (2019). Angka Harapan Hidup Prov Sumbar. Badan Pusat Statistik. Tersedia di <https://sumbar.bps.go.id/dynamictable/2019/10/18/32/angka-harapan-hidup-penduduk-provinsi-sumatera-barat-2010-2019-metode-baru-.html>- Diakses pada April 2020.
6. WHO (2018). Global Health Estimates 2016. Disease burden by Cause, Age, Sex, by Country and by Region 2000-2016. World Health Organization. Available from <https://www.who.int.healthinfo/globalburdendisease/estimates/en/index1.html>- Accessed on April 2020.
7. Kaplan SA. Factors in Predicting Failure with Medical Therapy for BPH. *Rev in urol.* 2005;7(7):34.
8. American Urology Association. Surgical Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia. AUA Guidelines Amandement. *J Urol.* 2019;202(3):592-8.
9. Smith JA, Howards SS, Preminger GM. Hinman's Atlas of Urologic Surgery, Expert Consult-Online and Print. 4th ed. Nashville: Elsevier Health Sciences;2012. p. 191-9.
10. Seki N, Naito S, Oshima S, Hirao Y, Higashihara E. Prevalence and Preference with Regard to Various Surgical Treatments for Benign Prostatic Hypertrophy: a survey for the Japanese endourology and ESWL society member. *Japan J Urol.* 2003;94(4):495-502.
11. NHS (2013). Prostatectomy or Transurethral Resection of the prostate (TURP). Tameside Hospital National Health Service Department of Urology. Available from www.tamesidehospital.nhs.uk – Accessed on June 2020.
12. Jeon BJ, Chung H, Bae JH, Jung H, Lee JG, Choi H. Analysis of Present Status for Surgery of Benign Prostatic Hyperplasia in Korea Using Nationwide Healthcare System Data. *Int Neurourol J.* 2019;23(1):22-9.
13. Ingimarsson JP, Isaksson HJ, Sigbjarnarson HP, Gudmundsson J, Geirsson G. Increased Population Use of Medications for Male Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia Correlates with Changes in Indications for Tansurethral Resection of The Prostate. *Scand J Urol.* 2014;48(1):73-8.
14. Halimi R, Pratama AR. Outcome Comparison of Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia Patients in Karawang General Referral Hospital. *Ina J of Cancer.* 2019;13(3):69-74.
15. Roar JK. Karakteristik Pasien Benign Prostate Hyperlasia (BPH) yang Menjalani Transurethral Resection of Prostate (TURP) di Rumah Sakit

- Umum Pusat Haji Adam Malik pada Periode Januari 2012-Desember 2013: Fak Kedokt Universitas Sumatera Utara; 2015.
16. Data Pasien BPH bagian bedah urologi RSUP Dr. M. Djamil Padang tahun 2016-2019.
 17. Amriyani. Pengaruh Transurethral Resection of the Prostate terhadap International Prostate Symptom Score Pada Pasien Benign Prostate Hyperplasia di Padang: Fak Kedokt Univ Andalas; 2020.
 18. Graham SD, Keane TE, Glenn JF. Glenn's urologic surgery. 8th ed. South Carolina: Lippincott Williams & Wilkins; 2010. p. 435-71.
 19. Snell, Richard S. Organ Genitalia Masculina, Penis, dan Scrotum. In: Snell, Richard S. Anatomis Klinis. Edisi ke-6. Jakarta: EGC;2006. hal. 786-9.
 20. Kumar V, Cotran RS, Robbins SL. Sistem Kelamin Laki-Laki dan Saluran Kemih Bawah. In: Himawan, Sutisna, translators. Buku ajar patologi. Edisi ke-9. Jakarta: Elsevier; 2015. hal. 655-7.
 21. Paulsen F, Waschke J. Sobotta Atlas Anatomi Manusia Jilid 2. Edisi ke-23. Pendit BU, Hartanto H, Nugroho AW, translators. Jakarta: EGC; 2012. hal. 190-3.
 22. Fawcett DW. Buku Ajar Histologi. Edisi ke-12. Tambayong J, translator. Jakarta: EGC; 2002. hal. 722.
 23. Suyono, Yoko. Sistem Reproduksi Pria. In: Eroschenko VP, translator. Atlas Histologi diFiore. Edisi ke-12. Jakarta: EGC; 2015. hal. 494-7.
 24. Widjajakusumah, Djauhari. Fungsi Reproduksi dan Hormonal Laki-Laki. In: Hall JE, Guyton AC, editors. Buku ajar fisiologi kedokteran. Edisi ke-12. Jakarta: Elsevier; 2011. hal. 933.
 25. Sherwood L. Fisiologi Manusia dari Sel ke Sistem. Edisi ke-7. Pendit BU, translator. Jakarta: EGC; 2011. hal. 705.
 26. Milonas D, Verikaite J, Jievaltas M. The Effect of Complete Transurethral Resection of the Prostate on Symptoms, Quality of Life, and Voiding Function Improvement. *Cent European J Urol*. 2015;68(2):169.
 27. Yasifa FG, Sugiharto S. Gambaran histopatologi hasil Transurethral Resection of Prostate (TURP) pada pasien pembesaran prostat di RS Sumber Waras periode tahun 2014–2016. *Tarumanegara Med J*. 2019;2(1):43-7.
 28. Alvarino AM. Perubahan International Prostate Symptom Score (IPSS) Pasca Pemberian Tamsulosin HCl 0, 4 mg pada Penderita Benign Prostatic Hyperplasia Non Retensi di Kota Padang: Fak Kedokt Univ Andalas Padang; 2019.
 29. Fitriana N, Zuhirman Z, Suyanto S. Hubungan Benign Prostate Hypertrophy dengan Disfungsi Ereksi di RSUD Arifin Achmad Provinsi Riau: Fak Kedokt Universitas Riau; 2014.
 30. Zuhirman Z, Juananda D, Lestari P. Gambaran Komplikasi Transurethral Resection of the Prostate pada Pasien Benign Prostatic Hyperplasia. *Med Sci J*. 2017;10(1):44-53.
 31. Chandrasegaran K. Gambaran Nilai International Prostate Symptom Score Pada Pasien Benign Prostate Hyperplasia Di Poliklinik Urologi RSUP Haji Adam Malik Medan: Fak Kedokt Universitas Sumatera Utara; 2013.

32. Maharajh S, Abdel Goad EH, Ramklass SS, Conradie MC. Lower Urinary Tract Symptoms (LUTS) in Males: a Review of Pathophysiology. *S Afr Fam Pract.* 2015; 57(2):88-92.
33. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA. Campbell-Walsh urology: expert consult premium edition: enhanced online features and print, 4-volume set. 11th ed. Cleveland: Elsevier Health Sciences;2011. p. 15078-87.
34. Yoo TK, Cho HJ. Benign Prostatic Hyperplasia: from bench to clinic. *Korean J Urol.* 2012; 53(3):139-48.
35. Nurmariana N. Gambaran Karakteristik dan Tingkat Keparahan Obstruksi Pasien Benign Prostatic Hyperplasia (BPH) di RSUD Dr. Soedarso Pontianak Tahun 2013: Fak Kedokt Universitas Tanjungpura; 2015.
36. Putra Y. Pengaruh Rokok Terhadap Jumlah Sel Spermatozoa Mencit Jantan (Mus Musculus, Strain Jepang). *Sainstek.* 2016; 6(1):30-42.
37. Amalia R. Faktor-Faktor Risiko Terjadinya Pembesaran Prostat Jinak (Studi Kasus Di RS Dr. Kariadi, RS Roemani Dan RSI Sultan Agung Semarang): Fak Kedokt Universitas Diponegoro; 2007.
38. Xia SJ, Cui D, Jiang Q. An Overview of Prostate Diseases and Their Characteristics Specific to Asian Men. *Asian J Urol.* 2012;14(3):458.
39. Grace PA, Borley NR. *At a Glance Ilmu Bedah.* Edisi ke-3. Surabaya: Erlangga; 2006. hal. 67-8.
40. Foo KT. Pathophysiology of Clinical Benign Prostatic Hyperplasia. *Asian J Urol.* 2017;4(3):152-7.
41. Schwartz SI, Shires GT, Spencer FT. *Intisari Prinsip-Prinsip Ilmu Bedah.* Edisi ke-6. Jakarta: EGC; 2000. hal. 592-3.
42. Pöyhönen A, Häkkinen JT, Koskimäki J, Hakama M, Tammela TL, Auvinen A. Empirical Evaluation of Grouping of Lower Urinary Tract Symptoms: principal component analysis of Tampere Ageing Male Urological Study data. *BJU Int.* 2013;111(3):467-73.
43. Fowler FJ, O'leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, Cockett AT. Measurement Committee of the American Urological Association. The American Urological Association symptom index for benign prostatic hyperplasia. *J urol.* 2017;197(2):189-97.
44. Barry MJ. Evaluation of Symptoms and Quality of Life in Men with Benign Prostatic Hyperplasia. *Urology.* 2001;58(6):25-32.
45. Tangel SJ, Monoarfa A, Monoarfa RA. Validasi International Prostate Symptom Score Versi Bahasa Indonesia pada Penderita Lower Urinary Tract Symptoms di Poliklinik Urologi RSUP Prof. Dr. RD Kandou Manado. *J Biomedik.* 2019;11(2):92-6.
46. Guzelsoy M, Aydos MM, Coban S, Turkoglu AR, Acibucu K, Demirci H. Comparison of the Effectiveness of IPSS and VPSS Without any Help in LUTS Patients: a prospective study. *The Aging Male.* 2018;21(3):193-9.
47. Putra IB, Hamid AR, Mochtar CA, Umbas R. Relationship of Age, Prostate-Specific Antigen, and Prostate Volume in Indonesian Men with Benign Prostatic Hyperplasia. *Prostate Int.* 2016;4(2):43-8.
48. Wulansari NS, Marindawati M. Profil Prostate Spesific Antigen (PSA) pada Penyakit Prostat di Rumah Sakit Umum Daerah Cengkareng Jakarta Barat. *Muhammadiyah J of Geriatric.* 2020;1(1):18-22.

49. Deori R, Das B, Rahman MA. A Study of Relationship of Prostate Volume, Prostate Specific Antigen, and Age in Benign Prostatic Hyperplasia. *Int J Contemp Med Res.* 2017;4(7):1582-6.
50. Sari YA, Duarsa GW, Mahadewa TG. Faktor Risiko yang Mempengaruhi Pembesaran Volume Prostat pada Pasien Pembesaran Prostat Jinak yang Dilakukan Reseksi Prostat Transuretra. *Medicina.* 2019;50(2):330-4.
51. Nickel JC. Benign prostatic hyperplasia: Does Prostate Size Matter?. *Rev in Urol.* 2003;5(4):12.
52. Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, et al. Clinical Outcomes After Combined Therapy with Dutasteride Plus Tamsulosin or Either Monotherapy in Men with Benign Prostatic Hyperplasia (BPH) by Baseline Characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. *BJU Int.* 2011;107(6):946-54.
53. Wiratama MA, Pardani PR. Hubungan Volume Prostat dan Protrusi Prostat Intravesika dengan Kejadian Retensi Urin Akut pada Pasien Benign Prostatic Hyperplasia di RSUD Buleleng Bulan Mei - Agustus Tahun 2017. *Medicina.* 2018;49(2):129-32.
54. Kim SJ, Alawamlh OA, Chughtai B, Lee RK. Lower Urinary Tract Symptoms Following Transurethral Resection of Prostate. *Curr Urol rep.* 2018;19(10):85.
55. Ni'am AZ. Faktor Risiko Terjadinya Retensi Urin Akut (AUR) Pada Pasien Benign Prostatic Hyperplasia (BPH) di RSUD Dr. SOETOMO Tahun 2016: Fak Kedokt Universitas Airlangga; 2018.
56. Gillig P. TURP Remains a Safe and Effective Alternative for Benign Prostatic Hyperplasia (BPH) Surgery. *BJU Int.* 2014;113(1):5-6.
57. Way LW, Doherty GM. Current Surgical Diagnosis & Treatment. 13rd ed. New York: Lange Medical Books/McGraw-Hill; 2003. p. 920-3.
58. UCF (2020). Surgery Treatment on BPH. Urology Care Foundation. Available from [https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-\(bph\)/treatment/surgery?article=31&article=31](https://www.urologyhealth.org/urologic-conditions/benign-prostatic-hyperplasia-(bph)/treatment/surgery?article=31&article=31) - Accessed May 2020.
59. Taneja SS, Shah O. Complications of Urologic Surgery E-Book: Prevention and Management. New York: Elsevier Health Sciences; 2017. p. 270-4.
60. Fiuk J, Nuss GR, Gonzalez CM. 2 Risk Factors For Urethral Stricture and Bladder Neck Contracture Following Transurethral Prostatectomy For BPH/LUTS. *J Urol.* 2012;187(4):1.
61. Yalcinkaya FR, Gokcei A, Davarci M, Guven EO, Inci M, Karta SB. The Impact of NIH-IV Prostatitis on Early Post Operative Outcomes of Transurethral Resection of The Prostate in Patients with Symptomatic Benign Prostate Hyperplasia. *Turk J Med Sci.* 2011;41(3):515-9.
62. Anutrakulchai S. Residual Lower Urinary Tract Symptoms (LUTS) After Transurethral Resection of Prostate (TURP): the urodynamic studies in Chiang Mai University Hospital. *Thai J Surg.* 2005;26:82-7.
63. Fontana M, Boeri L, Gallioli A, De Lorenzis E, Palmisano F, Zanetti SP, et al. Prevalence and Predictors of Being Lost to Follow-up After Transurethral Resection of the Prostate. *Sci rep.* 2018;8(1):1-7.

64. Magistro G, Stief CG, Woo HH. Mini-Review: What Is New in Urolift?. *Eur Urol Focus*. 2018;4(1):36-9.
65. Sachdeva RK. Catatan Ilmu Bedah. Edisi ke-5. Jakarta: Hipokrates;1996. hal. 245-9.
66. Dahlan S. Statistik Untuk Kedokteran dan Kesehatan K. Edisi ke-6. Jakarta: Salemba Medika; 2014. hal. 16.
67. Silalahi R, Simangunsong B, Siagian P. Karakteristik Penderita Penyakit Benign Prostatic Hyperplasia Di RS. Tk II Kesdam I Bukit Barisan Medan Sumatera Utara Tahun 2016. *Ked Methodist J*. 2018;11(1):261-4.
68. European Association of Urology. Management of Non-Neurogenic Male Lower Urinary Tract Symptoms (LUTS) Incl. Benign Prostatic Obstruction (BPO): European Association of Urology Guideline; 2020.
69. Khair LM. Hubungan Antara Volume Prostat dengan Kadar Prostate Spesific Antigen (PSA) Pada Pasien Benign Prostatic Hyperplasia (BPH) yang Menjalani Operasi Transurethral Resection of the Prostate (TURP) di RSUD Provinsi NTB Tahun 2012-2017: Fak Kedok Universitas Mataram; 2019.
70. Lim KB. Epidemiology of clinical benign prostatic hyperplasia. *Asian J Urol*. 2017;4(3):148-151.
71. Setiati S, Harimurti K, Govindra R. Proses menua dan implikasi kliniknya. In: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S, editor. Buku ajar ilmu penyakit dalam. Edisi ke-5. Jakarta: Internal Publishing;2009. hal. 757-65.
72. Rahman F, Putra, Ida B, Mochtar, Arif C, Rasyid, et al. Adherence of Indonesian urologists to practice guidelines for the management of benign prostatic hyperplasia. *Prostate Int*. 2018;7(1):35-40.
73. Kim JW, Oh MM, Park HS, Cheon J, Lee JG, Kim JJ, et al. Intravesical prostatic protrusion is a risk factor for bladder stone in patients with benign prostatic hyperplasia. *Urology*. 2014;84(5):1026-9.
74. Udoh E, Ekanem A. Pattern of serum creatinine and urea in patients seen with symptoms of bladder outlet obstruction. *Saudi J Med Pharm Sci*. 2016;2:185-9.
75. Bruno JP, Hugo C. Benign Prostate Hyperplasia and Chronic Kidney Disease. In: Ricardo L. Chronic Kidney Disease. Toronto: Intech; 2012. p. 347.
76. Lu CH, Wu HHH, Lin TP, Huang YH, Chung HJ, Kuo JY, et al. Is intravesical prostatic protrusion a risk factor for hydronephrosis and renal insufficiency in benign prostate hyperplasia patients? *J Chin Med Assoc*. 2019;82(5):381-4.
77. Lubetzky M, Ajaimy M, Kamal L, de Boccardo G, Akalin E, Kayler L. Kidney transplant complications from undiagnosed benign prostatic hypertrophy. *Clin Transplantation*. 2015;29(6):539-42.
78. Utami RI, Wahyudi SS, Hermansyah Y. Hubungan Prostate Volume dan Intravesical Prostatic Protrusion terhadap International Prostate Symptom Score pada Pasien Benign Prostate Hyperplasia. *Pustaka Kesehatan*. 2018;6(1):97-101.
79. Kuei CH, Liao CH, Chiang BJ. Significant intravesical prostatic protrusion and prostatic calcification predict unfavorable outcomes of medical

- treatment for male lower urinary tract symptoms. *Urol Sci.* 2016;27(1):13-6.
80. Topazio L, Perugia C, De Nunzio C. Intravesical prostatic protrusion is a predictor of alpha blockers response: results from an observational study. *BMC Urol.* 2018;18(1):1-5.
 81. Ladia Z. Usia dan Laju Pancaran Urin Maksimal Sebagai Prediktor Volume Prostat di RS Kepresidenan RSPAD Gatot Soebroto Pada Tahun 2016: Fak Kedokt Pembangunan Nasional Veteran Jakarta; 2017.
 82. Van SP, Heyns CF, Zarrabi AD. Comparison of men with acute versus chronic urinary retention: aetiology, clinical features and complications. *South African Family Practice.* 2011;53(6):590-4.
 83. Persu C, Georgescu D, Arabagiu I, Cauni V, Moldoveanu C, Geavlete P. TURP for BPH. How large is too large? *J Med Life.* 2010;3(4):376-80.
 84. Deori R, Das B, Rahman MA. A Study of Relationship of Prostate Volume, Prostate Specific Antigen, and Age in Benign Prostatic Hyperplasia. *Int J Contemp Med Res.* 2017;4(7):1582-6.
 85. Zhang SJ, Qian HN, Zhao Y, et al. Relationship between age and prostate size. *Asian J Androl.* 2013;15(1):116-20.
 86. Andaru M, Wibisono W, Wijanarko S. Hubungan Intravesical Prostatic Protrusion dan Post-Void Residual Urine dengan Lower Urinary Tract Symptoms pada Pasien Klinis Benign Prostatic Hyperplasia tanpa Retensi. *Biomedika.* 2018;10(1):20-9.
 87. Lee LS, Sim HG, Lim KB, Wang D, Foo KT. Intravesical Prostatic Protrusion Predicts Clinical Progression of Benign Prostatic Enlargement in Patients receiving Medical Treatment. *Int J Urol.* 2010;17(1):69-74.
 88. Sasanka KB, Simanta JN, Rajeev TP, Saumar JB, Phanindra MD, Bikash B. Correlation of Age, Prostate Volume, Serum Prostate-Specific Antigen, and Serum Testosterone in Indian, Benign Prostatic Hyperplasia Patients. *UroToday Int J.* 2012;5(5):43.
 89. Pejčić T, Acimović M, Dzamić Z, Radovanović M, Hadži D, Jovan. Benign prostatic hyperplasia and prostate-specific antigen. *Vojnosanitetski preglad.* 2015;72(5):447–53.
 90. Chawla R, Abraham R, Arora U, Mammen K. Effect of urinary retention on the levels of prostate specific antigen (PSA) and prostatic acid phosphatase (PAP) in prostatic disease. *Indian J Urol.* 2003;19(2):120.
 91. Antunes A, Alberto A, Sabrina T, Mary Guariero, Antonio M, Freire M, et al. Prostate biopsy in patients with long-term use of indwelling bladder catheter: What is the rationale?. *Urol Oncology.* 2012;30(5): 620–3.
 92. Izadpanahi M, Salimi H, Javid A, Eslami S. The effect of urethral catheterization on the level of prostate-specific antigen. *J Res Med Sci.* 2017;22:38.
 93. Aliasgari M, Soleimani M, Hosseini SM. The effect of acute urinary retention on serum prostate-specific antigen level. *J Urol.* 2005;2:89–92.
 94. Dharmawan NK, Duarsa GW. Infeksi saluran kemih berhubungan dengan peningkatan nilai prostate specific antigen pada pasien benign prostate hyperplasia di Rumah Sakit Sanglah. *E-J Medika Udayana.* 2018;7(5):230-3.

95. Patel, Devin N, Tom F, Ross M, Lauren H, Adriana C, et al. PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. *Prostate Cancer Prostatic*. 2018;21(2):238-44.
96. Yustina M, Duarsa GW, Oka AA, Wayan I. Hubungan prostate specific antigen (PSA) dengan rasio stromal epitelial prostat pada pasien pembesaran prostat jinak. *Medicina*. 2019;50(2):335-8.
97. Fu S, Zhang X , Niu Y, Wang R. Prostate specific antigen, mean platelet volume, and platelet distribution width in combination to discriminate prostate cancer from benign prostate hyperplasia. *Asian Pac J Cancer Prev*. 2018;19(3):699.
98. Madersbacher S, Lackner J, Brössner C, Röhlich M, Stancik I, Willinger M, et al. Prostate Study Group of the Austrian Society of Urology Reoperation, myocardial infarction and mortality after transurethral and open prostatectomy: a nation-wide, long-term analysis of 23,123 cases. *Eur Urol*. 2005;47(4):499-504.
99. Chughtai B, Lee R, Te A, Kaplan S. Role of inflammation in benign prostatic hyperplasia. *Rev Urol*. 2011;13(3):147.
100. Duarsa GW, Dau DO, Pramana IB, Tirtayasa PM, Yudiana IW, Santosa KB, et al. Risk Factors for Prostate Volume Progression After Prostate-Transurethral Resection. *Res Rep Urol*. 2020;12:175.

